<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37373545</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Doubtful Clinical Value of Subtyping Anti-U1-RNP Antibodies Regarding the RNP-70 kDa Antigen in Sera of Patients with Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10398</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241210398</ELocationID><Abstract><AbstractText>The detection of antinuclear antibodies is central to the diagnosis and prognosis of systemic lupus erythematosus (SLE), primary Sj&#xf6;gren's syndrome (pSS) and mixed connective tissue disease (MCTD). Anti-U1-RNP and anti-RNP70 antibodies were assayed in the sera of patients with SLE (<i>n</i> = 114), pSS (<i>n</i> = 54) and MCTD (<i>n</i> = 12). In the SLE group, 34/114 (30%) were anti-U1-RNP positive, and 21/114 (18%) were both anti-RNP70 positive and anti-U1-RNP positive. In the MCTD group, 10/12 (83%) were anti-U1-RNP positive, and 9/12 (75%) were anti-RNP70 positive. Only one individual with pSS was antibody positive (for both anti-U1-RNP and anti-RNP70). All anti-RNP70-positive samples were also anti-U1-RNP positive. Anti-U1-RNP-positive subjects with SLE were younger (<i>p</i> &lt; 0.0001); showed lower concentrations of complement protein 3 (<i>p</i> = 0.03); had lower eosinophil (<i>p</i> = 0.0005), lymphocyte (<i>p</i> = 0.006) and monocyte (<i>p</i> = 0.03) counts; and had accrued less organ damage (<i>p</i> = 0.006) than the anti-U1-RNP-negative SLE patients. However, we observed no significant clinical or laboratory parameter differences between the anti-U1-RNP-positive individuals with/without anti-RNP70 in the SLE group. In conclusion, anti-RNP70 antibodies are not exclusive to MCTD but are rarely detected in pSS and healthy individuals. In SLE, anti-U1-RNP antibodies are associated with a clinical phenotype that resembles MCTD, with hematologic involvement and less damage accrual. Based on our results, the clinical value of subtyping anti-RNP70 in anti-U1-RNP-positive sera appears to be of limited value.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Awais</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3252-5528</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Clinical Immunology &amp; Transfusion Medicine, Link&#xf6;ping University, SE-581 85 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brylid</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Clinical Immunology &amp; Transfusion Medicine, Link&#xf6;ping University, SE-581 85 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahle</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Clinical Immunology &amp; Transfusion Medicine, Link&#xf6;ping University, SE-581 85 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleh</LastName><ForeName>Muna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4836-6373</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Link&#xf6;ping University, SE-581 85 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahlstr&#xf6;m</LastName><ForeName>&#xd6;rjan</ForeName><Initials>&#xd6;</Initials><Identifier Source="ORCID">0000-0002-3955-0443</Identifier><AffiliationInfo><Affiliation>Department of Behavioural Sciences and Learning, Swedish Institute for Disability Research, Link&#xf6;ping University, SE-581 83 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enocsson</LastName><ForeName>Helena</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2125-2931</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Link&#xf6;ping University, SE-581 85 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sj&#xf6;wall</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0900-2048</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Link&#xf6;ping University, SE-581 85 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Grant nr R-939149</GrantID><Agency>Swedish Rheumatism Association</Agency><Country/></Grant><Grant><GrantID>ALF Grants; Grant nr R&#xd6;-960604</GrantID><Agency>Region &#xd6;sterg&#xf6;tland</Agency><Country/></Grant><Grant><GrantID>Grant nr 2023-36</GrantID><Agency>Gustafsson Foundation</Agency><Country/></Grant><Grant><GrantID>Grant nr FAI-2020-0663</GrantID><Agency>King Gustaf V's 80-year Anniversary Foundation</Agency><Country/></Grant><Grant><GrantID>Grant nr 2021</GrantID><Agency>King Gustaf V and Queen Victoria's Freemasons Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000719007">anti-small nuclear ribonucleoproteins autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490688">SNRNP70 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017412">Ribonucleoprotein, U1 Small Nuclear</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="Y">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017412" MajorTopicYN="N">Ribonucleoprotein, U1 Small Nuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008947" MajorTopicYN="N">Mixed Connective Tissue Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">mixed connective tissue disease</Keyword><Keyword MajorTopicYN="N">primary Sj&#xf6;gren&#x2019;s syndrome</Keyword><Keyword MajorTopicYN="N">small nuclear ribonucleoprotein antibodies</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflict of interest. The funders had no role in the design of the study; the collection, analysis or interpretation of the data; or in the writing of the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37373545</ArticleId><ArticleId IdType="pmc">PMC10299012</ArticleId><ArticleId IdType="doi">10.3390/ijms241210398</ArticleId><ArticleId IdType="pii">ijms241210398</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Damoiseaux J., Andrade L.E.C., Carballo O.G., Conrad K., Francescantonio P.L.C., Fritzler M.J., Garcia de la Torre I., Herold M., Klotz W., Cruvinel W.M., et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: The International Consensus on ANA patterns (ICAP) perspective. Ann. Rheum. Dis. 2019;78:879&#x2013;889. doi: 10.1136/annrheumdis-2018-214436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214436</ArticleId><ArticleId IdType="pmc">PMC6585284</ArticleId><ArticleId IdType="pubmed">30862649</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen N.J., Karp D.R. Autoantibodies and SLE: The threshold for disease. Nat. Rev. Rheumatol. 2014;10:181&#x2013;186. doi: 10.1038/nrrheum.2013.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2013.184</ArticleId><ArticleId IdType="pubmed">24296678</ArticleId></ArticleIdList></Reference><Reference><Citation>Didier K., Bolko L., Giusti D., Toquet S., Robbins A., Antonicelli F., Servettaz A. Autoantibodies Associated with Connective Tissue Diseases: What Meaning for Clinicians? Front. Immunol. 2018;9:541. doi: 10.3389/fimmu.2018.00541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00541</ArticleId><ArticleId IdType="pmc">PMC5879136</ArticleId><ArticleId IdType="pubmed">29632529</ArticleId></ArticleIdList></Reference><Reference><Citation>Frodlund M., Wetter&#xf6; J., Dahle C., Dahlstr&#xf6;m &#xd6;., Skogh T., R&#xf6;nnelid J., Sj&#xf6;wall C. Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: A prospective study of Swedish cases with recent-onset disease. Clin. Exp. Immunol. 2020;199:245&#x2013;254. doi: 10.1111/cei.13402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13402</ArticleId><ArticleId IdType="pmc">PMC7008226</ArticleId><ArticleId IdType="pubmed">31778219</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliorini P., Baldini C., Rocchi V., Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity. 2005;38:47&#x2013;54. doi: 10.1080/08916930400022715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930400022715</ArticleId><ArticleId IdType="pubmed">15804705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kattah N.H., Kattah M.G., Utz P.J. The U1-snRNP complex: Structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol. Rev. 2010;233:126&#x2013;145. doi: 10.1111/j.0105-2896.2009.00863.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0105-2896.2009.00863.x</ArticleId><ArticleId IdType="pmc">PMC3074261</ArticleId><ArticleId IdType="pubmed">20192997</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemekasten G., Hahn B.H. Key autoantigens in SLE. Rheumatology (Oxford) 2005;44:975&#x2013;982. doi: 10.1093/rheumatology/keh688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh688</ArticleId><ArticleId IdType="pubmed">15901907</ArticleId></ArticleIdList></Reference><Reference><Citation>De Keyser F., Hoch S.O., Takei M., Dang H., De Keyser H., Rokeach L.A., Talal N. Cross-reactivity of the B/B&#x2032; subunit of the Sm ribonucleoprotein autoantigen with proline-rich polypeptides. Clin. Immunol. Immunopathol. 1992;62:285&#x2013;290. doi: 10.1016/0090-1229(92)90104-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-1229(92)90104-V</ArticleId><ArticleId IdType="pubmed">1371727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg I., Nyman U., Pettersson I., Hedfors E. Clinical manifestations and anti-(U1)snRNP antibodies: A prospective study of 29 anti-RNP antibody positive patients. Br. J. Rheumatol. 1992;31:811&#x2013;817. doi: 10.1093/rheumatology/31.12.811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/31.12.811</ArticleId><ArticleId IdType="pubmed">1458287</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmhofer W., Hermann J., Joch M., Kerl H., Graninger W. High serum levels of antibodies against the recombinant 70 kDa ribonucleoprotein are useful for diagnosing mixed connective tissue disease. J. Eur. Acad. Dermatol. Venereol. 2007;21:1047&#x2013;1053. doi: 10.1111/j.1468-3083.2007.02163.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-3083.2007.02163.x</ArticleId><ArticleId IdType="pubmed">17714123</ArticleId></ArticleIdList></Reference><Reference><Citation>Montecucco C., Caporali R., Ravelli A., Ronchetti A., Rossi S., Martini A., Notario A. Frequency and clinical significance of anti-RNP antibodies in Italian SLE patients. Ann. Ital. Med. Int. 1994;9:12&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">8003386</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n-Segovia D., Cardiel M.H. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J. Rheumatol. 1989;16:328&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">2724251</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani C., Carli L., Vagnani S., Talarico R., Baldini C., Mosca M., Bombardieri S. The diagnosis and classification of mixed connective tissue disease. J. Autoimmun. 2014;48&#x2013;49:46&#x2013;49. doi: 10.1016/j.jaut.2014.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2014.01.008</ArticleId><ArticleId IdType="pubmed">24461387</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves M.R., Isenberg D.A. &#x201c;Mixed connective tissue disease&#x201d;: A condition in search of an identity. Clin. Exp. Med. 2020;20:159&#x2013;166. doi: 10.1007/s10238-020-00606-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-020-00606-7</ArticleId><ArticleId IdType="pmc">PMC7181542</ArticleId><ArticleId IdType="pubmed">32130548</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter J.B., Shoenfeld Y., editors. Autoantibodies. 1st ed. Elsevier Science; Amsterdam, The Netherlands: 1996. Spliceosomal snRNPs Autoantibodies; pp. 774&#x2013;782.</Citation></Reference><Reference><Citation>Tan E.M. Autoantibodies in Diagnosis and in Identifying Autoantigens. Immunologist. 1999;7:85&#x2013;92.</Citation></Reference><Reference><Citation>Venrooij W.J.V., Maini R.N., editors. Manual of Biological Markers of Disease. Kluwer Academic Publishers; Dordecht, The Netherlands: 1996. Anti-U1snRNP antibodies and clinical associations; pp. 1&#x2013;8.</Citation></Reference><Reference><Citation>Nawata M., Matsushita M., Matsudaira R.A.N., Yamada H., Kaneda K., Asano M., Yamanaka K., Murakami A., Takasaki Y. Clinical Significance of Anti-U1 RNP Antibodies Recognizing the Conformation Structure on U1 RNA/70-kd Protein Complex in Patients with Mixed Connective Tissue Disease. Juntendo Med. J. 2011;57:477&#x2013;487. doi: 10.14789/pjmj.57.477.</Citation><ArticleIdList><ArticleId IdType="doi">10.14789/pjmj.57.477</ArticleId></ArticleIdList></Reference><Reference><Citation>Irure-Ventura J., L&#xf3;pez-Hoyos M. The Past, Present, and Future in Antinuclear Antibodies (ANA) Diagnostics. 2022;12:647. doi: 10.3390/diagnostics12030647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12030647</ArticleId><ArticleId IdType="pmc">PMC8946865</ArticleId><ArticleId IdType="pubmed">35328200</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow M.K., R&#xf6;nnblom L. Type I interferons in host defence and inflammatory diseases. Lupus Sci. Med. 2019;6:e000336. doi: 10.1136/lupus-2019-000336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000336</ArticleId><ArticleId IdType="pmc">PMC6541752</ArticleId><ArticleId IdType="pubmed">31205729</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbara S., Seror R., Henry J., Chretien P., Gleizes A., Hacein-Bey-Abina S., Mariette X., Nocturne G. Anti-RNP positivity in primary Sj&#xf6;gren&#x2019;s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement. RMD Open. 2019;5:e001033. doi: 10.1136/rmdopen-2019-001033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2019-001033</ArticleId><ArticleId IdType="pmc">PMC6802987</ArticleId><ArticleId IdType="pubmed">31673417</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda K.M., Yoshizaki A., Yamaguchi K., Fukuda E., Okumura T., Ogawa K., Ono C., Norimatsu Y., Kotani H., Hisamoto T., et al. Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status. Front. Immunol. 2022;13:893086. doi: 10.3389/fimmu.2022.893086.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.893086</ArticleId><ArticleId IdType="pmc">PMC9114879</ArticleId><ArticleId IdType="pubmed">35603173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbard E.L., Pisetsky D.S., Lipsky P.E. Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE. Ann. Rheum. Dis. 2022;81:632&#x2013;643. doi: 10.1136/annrheumdis-2021-221662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221662</ArticleId><ArticleId IdType="pubmed">35115332</ArticleId></ArticleIdList></Reference><Reference><Citation>Dima A., Jurcut C., Baicus C. The impact of anti-U1-RNP positivity: Systemic lupus erythematosus versus mixed connective tissue disease. Rheumatol. Int. 2018;38:1169&#x2013;1178. doi: 10.1007/s00296-018-4059-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-018-4059-4</ArticleId><ArticleId IdType="pubmed">29796907</ArticleId></ArticleIdList></Reference><Reference><Citation>Ighe A., Dahlstr&#xf6;m &#xd6;., Skogh T., Sj&#xf6;wall C. Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register. Arthritis Res. Ther. 2015;17:3. doi: 10.1186/s13075-015-0521-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0521-9</ArticleId><ArticleId IdType="pmc">PMC4318183</ArticleId><ArticleId IdType="pubmed">25575961</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths B., Mosca M., Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract. Res. Clin. Rheumatol. 2005;19:685&#x2013;708. doi: 10.1016/j.berh.2005.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2005.03.010</ArticleId><ArticleId IdType="pubmed">16150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., Daniels T.E., Fox P.C., Fox R.I., Kassan S.S., et al. Classification criteria for Sj&#xf6;gren&#x2019;s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 2002;61:554&#x2013;558. doi: 10.1136/ard.61.6.554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.61.6.554</ArticleId><ArticleId IdType="pmc">PMC1754137</ArticleId><ArticleId IdType="pubmed">12006334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>